The U.S. Food and Drug Administration approved Marlborough, Massachusetts-based Sunovion Pharmaceuticals’ Kynmobi (apomorphine HCl) sublingual film for Parkinson’s disease.

Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here is a look at what is on the schedule for the next two weeks.

Acorda Therapeutics will terminate approximately 25 percent of headcount as the company initiates a corporate restructuring.

The U.S. FDA approved Kyowa Kirin’s Nourianz (istradefylline) as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “off” episodes.

The U.S. Food and Drug Administration rejected Sunovion Pharmaceuticals’ experimental treatment apomorphine sublingual film (APL-130277) for OFF episodes of Parkinson’s disease.

The U.S. FDA approved Acorda Therapeutics’ Inbrija, the first inhaled formula of levodopa (L-dopa) for the intermittent treatment of OFF episodes in Parkinson’s disease patients.